Physician
Internal Medicine
Dr. William R. Sellers, MD
|
|
Give Review
William R. Sellers, MD practices Internal Medicine. He attended University of Massachusetts Medical School. University of Massachusetts Medical School is ranked 49 in research and 12 in primary care medicine He has 1 awards "Elected Member". William Sellers is a published doctor. He has 89 papers published. The most current publication "Disordered methionine metabolism in MTAP/CDKN2A deleted cancers leads to dependence on PRMT5."
Publications
- Disordered methionine metabolism in MTAP/CDKN2A deleted cancers leads to dependence on PRMT5.
- High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
- Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.
- Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
- Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling.
- Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
- Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.
- An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin.
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide).
- Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.
- Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer.
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
- Twenty-fourth Annual Pezcoller Symposium: Molecular Basis for Resistance to Targeted Agents.
- FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor.
- Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations.
- THE NOVEL ORAL HSP90 INHIBITOR NVP-HSP990 EXHIBITS POTENT AND BROAD-SPECTRUM ANTI-TUMOR ACTIVITIES IN VITRO AND IN VIVO.
- Identification and characterization of NVP-BKM120, an orally available pan class I PI3-Kinase inhibitor.
- Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/{beta}-catenin signaling.
- A blueprint for advancing genetics-based cancer therapy.
- FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF23 signaling and regulating FGF23 expression in bone.
- A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
- Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.
- Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.
- PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
- Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies.
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.
- The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells.
- An oncogenic role for ETV1 in melanoma.
- MEK1 mutations confer resistance to MEK and B-RAF inhibition.
- Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.
- p85 Associates with unphosphorylated PTEN and the PTEN-associated complex.
- AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
- Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.
- PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
- Single-vector inducible lentiviral RNAi system for oncology target validation.
- Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
- A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression.
- Drug-sensitive FGFR2 mutations in endometrial carcinoma.
- PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression.
- Modeling genomic diversity and tumor dependency in malignant melanoma.
- A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling.
- Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.
- Identification of prostate cancer modifier pathways using parental strain expression mapping.
- A 2-Mb critical region implicated in the microcephaly associated with terminal 1q deletion syndrome.
- High-throughput oncogene mutation profiling in human cancer.
- Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
- TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.
- Mechanistic insights into maintenance of high p53 acetylation by PTEN.
- Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing.
- Development of an integrated prostate cancer research information system.
- Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays.
- Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth fac...
- Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane.
- From integrated genomics to tumor lineage dependency.
- Seventeenth Annual Pezcoller Symposium: molecular understanding of solid tumors.
- Amplification and overexpression of prosaposin in prostate cancer.
- Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
- Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
- Allele-specific amplification in cancer revealed by SNP array analysis.
- Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle p...
- p63 regulates commitment to the prostate cell lineage.
- Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.
- Selective ablation of retinoblastoma protein function by the RET finger protein.
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
- EGFR gene mutations: a call for global x global views of cancer.
- Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
- Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells.
- Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment.
- Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
- Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis.
- High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene.
- Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types.
- The biology and clinical relevance of the PTEN tumor suppressor pathway.
- Molecular characterization of the tumor microenvironment in breast cancer.
- EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
- mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.
- Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.
- An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays.
- Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.
- Use of expression analysis to predict outcome after radical prostatectomy.
- A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells.
- Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioin...
- TSC2 regulates VEGF through mTOR-dependent and -independent pathways.
- Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.
- Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft.
- The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer?
- A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR.
- Gene expression correlates of clinical prostate cancer behavior.
Schools
University of Massachusetts Worcester Campus
Dana Farber Canc Institute Harva
Doctors Specialties
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Awards
- Elected Member
Education
-
Brigham and Women's Hospital -
UCSF -
University of Massachusetts Medical School
Helpful Reviews
Similar Doctors
|
|
Aliya R. Laeeq |
|
|
Dr. George W. Thorn, MD |
|
|
Dr. Gregg D. Fine, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew L. Sherman, MD |
|
|
Dr. Naveed Aslam, MD
This Doctor is OpenDoctor Recommended.
|